

Reference:	FOI.20228.26
Subject:	Oncology treatments
Date of Request:	17 April 2026

Requested:

I am submitting this request under the Freedom of Information Act 2000 regarding private oncology services and prescribing within the Trust.

Additionally, if certain data points are not recorded in the exact format requested, I would welcome any alternative figures or insights.

When referring to a private patient this is a patient treated within NHS facilities but not funded by the NHS.

Oncology Services

1. Please confirm the number of patients treated for cancer by patient type for the calendar year (2025).

Number of Oncology patients (Calendar year 2025)	Patients
Total	
NHS Funded	
Privately Funded	

Prescribing of specific Immuno-oncology products.

2. For the latest calendar year (2025), please provide the number of patients treated with the following Immuno-oncology products:

Number of Oncology patients treated with the following Immuno-oncology product (Calendar year 2025)	Patients: Pembrolizumab (Keytruda)	Patients: Zanubrutinib (Brukinsa)	Patients: Acalabrutinib (Calquence)
Total			
NHS Funded			
Privately Funded			

Response:

Hywel Dda University Health Board (UHB) does not hold all the information requested, as it does not treat private patients.

1. The UHB confirms that it treated two thousand, eight hundred and twenty-three (2,823) patients for cancer, during the 2025 calendar year.
2. The UHB provides within the table overleaf, the number of cancer patients treated with the Immuno-oncology products requested, during the 2025 calendar year.

	Product	Number	
	Pembrolizumab (Keytruda)	212	
	Zanubrutinib (Brukinsa)	24	
	Acalabrutinib (Calquence)	21	